<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>29137875</identifier>
<setSpec>2253-8070</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Gómez-de la Fuente, F J</dc:author>
<dc:author>Quirce, R</dc:author>
<dc:author>Jiménez-Bonilla, J</dc:author>
<dc:author>Martínez-Rodríguez, I</dc:author>
<dc:author>Banzo, I</dc:author>
<dc:author>Martínez-Amador, N</dc:author>
<dc:author>de Arcocha-Torres, M</dc:author>
<dc:description xml:lang="en">OBJECTIVE 11C-choline PET/CT has demonstrated good results in the restaging of prostate cancer (PCa) with high serum prostate specific antigen (PSA), but its use in patients with low serum PSA is controversial. Our aim was to evaluate the contribution of 11C-choline PET/CT in patients with PCa, biochemical relapse and PSA &lt;1 ng/ml. MATERIAL AND METHOD Fifty consecutive patients (mean age: 65.9±5.6 years) with biochemical relapse of PCa and serum PSA &lt;1ng/ml were evaluated retrospectively. PET/CT was performed 20min after intravenous administration of 555-740 MBq of 11C-choline. Minimum follow up time was 30 months. RESULTS Twenty-one out of 50 patients (42%) had an abnormal 11C-choline PET/CT. In 7 out of 21 patients (14%) tumor was confirmed (4 in prostatic bed, 4 in pelvic lymph nodes, 2 in mediastinal lymph nodes and one synchronous sigmoid carcinoma), and in all cases the initial therapeutic planning was modified. In 2 patients (4%) subsequent tests diagnosed a benign disease (one sarcoidosis, one tuberculosis sequelae) and in 3 patients (6%) they ruled out pathology. The other 9 patients (18%) had no further assessment (7 mediastinal and 4 pelvic lymph nodes). Twenty-nine out of 50 patients (58%) had a normal PET/CT. At 30 months, follow up recurrence was confirmed only in 2 of these patients. CONCLUSIONS 11C-choline PET/CT proved its usefulness in demonstrating tumor in 14% of patients with BR of PCa and serum PSA &lt;1ng/ml, with therapeutic implications. In 4% of patients a benign condition was detected. A normal 11C-choline PET/CT was associated with a very low rate of recurrence at 30 months.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Cáncer de próstata</dc:subject>
<dc:subject>Biochemical relapse</dc:subject>
<dc:subject>(11)C-choline</dc:subject>
<dc:subject>(11)C-colina</dc:subject>
<dc:subject>Serum PSA</dc:subject>
<dc:subject>Positron emission tomography/computed tomography</dc:subject>
<dc:subject>Recidiva bioquímica</dc:subject>
<dc:subject>Prostate cancer</dc:subject>
<dc:subject>Antígeno específico prostático sérico</dc:subject>
<dc:subject>Tomografía por emisión de positrones/tomografía computarizada</dc:subject>
<dc:date>2017 Nov 11 </dc:date>
<dc:title xml:lang="es">Aportación de la PET/TC con 11C-colina en la recidiva bioquímica del cáncer de próstata con antígeno específico prostático sérico inferior a 1 ng/ml.</dc:title>
<dc:title xml:lang="en">Contribution of 11C-Choline PET/CT in prostate carcinoma biochemical relapse with serum PSA level below 1 ng/ml.</dc:title>
<dc:publisher>Revista espanola de medicina nuclear e imagen molecular</dc:publisher>
</metadata>
</record>
</pubmed-document>
